Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12489940 | 0.98 | TBXAS1 (0.49) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 | |
| SCHEMBL29224134 | 0.98 | TBXAS1 (0.49) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 | |
| SCHEMBL20511895 | 0.85 | TBXAS1 (0.44) | TBXAS1TPSAB1TPSD1TPSG1HRH3 | |
| SCHEMBL28944847 | 0.85 | TBXAS1 (0.44) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 | |
| SCHEMBL15070097 | 0.85 | TBXAS1 (0.44) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 | |
| SCHEMBL12016571 | 0.84 | TPSAB1 (0.44) | TBXAS1TPSAB1TPSD1TPSG1HRH3 | |
| SCHEMBL14875386 | 0.83 | TBXAS1 (0.43) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 | |
| SCHEMBL23604884 | 0.82 | TBXAS1 (0.42) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 | |
| SCHEMBL26132942 | 0.81 | TBXAS1 (0.43) | TBXAS1TPSAB1TPSD1TPSG1MAPT | |
| SCHEMBL12489979 | 0.81 | TBXAS1 (0.39) | TBXAS1TPSAB1TPSD1TPSG1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| US-20220233566-A1 | NOVEL CARBONATE COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-3988174-A1 | NOVEL CARBONATE COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993877-A | Novel carbonate compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof | 大鹏药品工业株式会社 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020255979-A1 | NOVEL CARBONATE COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大鵬薬品工業株式会社 | 2020-12-24 | — | — | WO | disclosed |
| EP-3601216-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172852-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-09-27 | — | — | WO | disclosed |
| US-9162223-B2 | Alkaline-stable chromatographic resins | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162223-B2 | Alkaline-stable chromatographic resins | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130165539-A1 | ALKALINE-STABLE CHROMATOGRAPHIC RESINS | NORTH CAROLINA STATE UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233566-A1 | NOVEL CARBONATE COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TYMP, SLC20A1, MGMT | TBXAS1 2074/4885TPSAB1 4024/4885TPSD1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.